Clinical Trial Update: Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Yttrium-90 ibritumomab tiuxetan (Zevalin) with BEAM conditioning in relapsed low-grade B-cell lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Carmustine (BiCNU) (carmustine)
• Cytarabine (Ara-C) (cytarabine)
• Etoposide (VePesid) (Etoposide)
• Melphalan (Alkeran) (melphalan)
• ibritumomab tiuxetan (Zevalin) (ibritumomab tiuxetan)

Snippet

Sponsor: Lymphoma Study Association | Conditions: B-Cell Lymphoma | Phase 2 | Status: COMPLETED